Boehringer Ingelheim’s survodutide shows breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
07 juin 2024 04h30 HE
|
Boehringer Ingelheim
News builds on previously announced primary endpoint, which showed up to 83.0% of adults achieved statistically significant improvement in metabolic dysfunction-associated steatohepatitis (MASH)...
Gyre Therapeutics Announces Expected Addition to the Russell 2000® and Russell 3000® Indexes
28 mai 2024 16h05 HE
|
Gyre Therapeutics, Inc.
Gyre Therapeutics Announces Expected Addition to the Russell 2000® and Russell 3000® Indexes
Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
09 mai 2024 16h10 HE
|
Gyre Therapeutics, Inc.
Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Clinical ink announces GlucoseReady™
23 avr. 2024 08h00 HE
|
Clinical Ink
Winston Salem, NC, April 23, 2024 (GLOBE NEWSWIRE) -- Clinical ink, a global life science technology company, today announced the launch of GlucoseReady™, a fully integrated GCP compliant digital...
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
15 avr. 2024 08h05 HE
|
Organovo, Inc.
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Conte
Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis
09 avr. 2024 08h00 HE
|
Madrigal Pharmaceuticals, Inc.
Rezdiffra is the first and only medication approved by the FDA for the treatment of NASH (also known as “MASH”) First patients have received Rezdiffra via Madrigal’s specialty pharmacy network ...
US Gastroenterologists Project Swift Uptake of Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)
05 avr. 2024 09h17 HE
|
Spherix Global Insights
EXTON, PA, April 05, 2024 (GLOBE NEWSWIRE) -- As the first treatment to gain FDA approval for metabolic dysfunction-associated steatohepatitis (MASH), Madrigal Pharmaceuticals’ Rezdiffra...
Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
26 mars 2024 06h00 HE
|
Gyre Therapeutics, Inc.
Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
Gyre Therapeutics Expands Board of Directors with Appointment of Rodney L. Nussbaum
21 mars 2024 07h00 HE
|
Gyre Therapeutics, Inc.
Gyre Therapeutics Expands Board of Directors with Appointment of Rodney L. Nussbaum
FDA’s Approval of Breakthrough NASH Treatment Opens Door for a Long-Neglected Patient Population
14 mars 2024 17h18 HE
|
Global Liver Institute
Washington, DC, March 14, 2024 (GLOBE NEWSWIRE) -- Today, Global Liver Institute (GLI) recognizes the importance of the first approval by the U.S. Food and Drug Administration (FDA) of a medication...